WeVote
Log In

Bill

YA

Bill

HR 8160

Premenstrual Dysphoric Disorder Awareness and Research Act of 2026

119th Congress Introduced by Yassamin Ansari and 27 co-sponsors

The bill would boost PMDD awareness, fund research, and expand education for clinicians and patients to improve diagnosis and access to evidence-based treatments.

Introduced in House
0
WeVote Research Nonpartisan
Bill Summary · HR 8160

Overview

HR 8160, the Premenstrual Dysphoric Disorder Awareness and Research Act of 2026, is a federal bill introduced in the 119th Congress. The measure seeks to raise awareness about Premenstrual Dysphoric Disorder (PMDD), promote research, and support educational and clinical efforts related to PMDD. It has a broad group of co-sponsors from both parties and multiple committees may oversee its provisions, with initial referral to the House Committee on Energy and Commerce.

Purpose and Intent

  • Increase public and professional awareness of PMDD as a recognized mental health condition affecting individuals who menstruate.
  • Promote federally supported research to better understand the causes, diagnosis, treatment, and outcomes associated with PMDD.
  • Support education and training for healthcare professionals and for individuals affected by PMDD to improve recognition, diagnosis, and management.
  • Potentially enhance access to evidence-based interventions and resources.

Key Provisions (as typically included in this type of bill)

Note: The exact text of HR 8160 is not provided here, but the bill is described as focusing on awareness, research, and education. Expected or typical provisions may include:

  • Authorization or direction for federal agencies (e.g., Department of Health and Human Services, National Institutes of Health) to fund PMDD-specific research initiatives or to coordinate PMDD research efforts.
  • Establishment or support of PMDD awareness campaigns targeting the public, patients, and healthcare providers.
  • Grants or programmatic activities to improve medical education and training related to PMDD, including recognition of symptoms, diagnostic criteria, and treatment options.
  • Development of informational materials, patient resources, and clinical guidance to improve early identification and management.
  • Data collection, surveillance, or reporting requirements to better quantify PMDD prevalence, treatment gaps, and outcomes.
  • Coordination with existing mental health, women's health, and reproductive health initiatives.

Affected Parties and Impacts

  • Individuals experiencing PMDD: Potential improvements in awareness, diagnosis, and access to evidence-based treatments due to educational efforts and enhanced resources.
  • Healthcare professionals: Training and informational resources to improve recognition and management of PMDD.
  • Researchers and institutions: Access to funding opportunities and federal support for PMDD-focused studies.
  • Federal agencies: Possible new or expanded programs, reporting requirements, and interagency collaboration to advance PMDD research and awareness.
  • General public: Broader awareness about PMDD as a health condition, reducing stigma and misinformation.

Procedural and Timeline Aspects

  • Action History indicates the bill was introduced and referred to the House Committee on Energy and Commerce on March 30, 2026.
  • As a first-step measure, committee consideration would be expected, followed by potential floor action, markups, and votes.
  • Any implementation would depend on subsequent appropriations or authorizations, and potential alignment with broader health or women’s health initiatives.

Practical Considerations

  • The bill emphasizes nonpartisan goals of better understanding and addressing PMDD through research and education.
  • Funding levels, specific programs, and mandatory versus voluntary activities would be clarified in the bill’s text and any amended versions.
  • If enacted, coordination with NIH, FDA (for any diagnostic or treatment guidance), and CDC (for surveillance and education) could be anticipated.

If you’d like, I can tailor this summary to emphasize particular aspects (e.g., funding mechanisms, anticipated agencies involved, or comparison with related legislation) or wait for the bill’s full text to extract exact provisions and numeric details.

Compiled from official sources — confirm details with the bill’s official record.

Sign in to ask a question.